Decade of Progress in Motor Functional Neurological Disorder

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Neuropsychiatry J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-323953 on 15 March 2021. Downloaded from Review Decade of progress in motor functional neurological disorder: continuing the momentum David L Perez ,1 Mark J Edwards,2 Glenn Nielsen,2 Kasia Kozlowska,3 Mark Hallett ,4 W Curt LaFrance, Jr 5 ► Additional material is ABSTRACT specificity, an expanding ‘toolbox’ of treatments published online only. To view, Functional neurological disorder (FND) is a prevalent, and new pathophysiological models that embrace please visit the journal online patient- centred biopsychosocial formulations.3 A (http:// dx. doi. org/ 10. 1136/ disabling and costly condition at the neurology– jnnp- 2020- 323953). psychiatry intersection. After being marginalised in the newly formed professional society ( www. fndsociety. late 20th century, there has been renewed interest org), authoritative FND textbooks4 5 and recent 1Neurology and Psychiatry, in this field. In this article, we review advances that special journal issues on this topic have further Massachusetts General Hospital, have occurred over the past decade (2011–2020) energised clinical and research efforts in FND. Boston, Massachusetts, USA 2Neuroscience Research Centre, across diagnosis, mechanisms, aetiologies, treatments In this narrative review, we highlight important St George’s University of and stigma in patients with motor FND (mFND, that advancements and their implications for motor London, London, UK is, functional movement disorder and functional limb FND (mFND) over the past 10 years (2011–2020)— 3 Westmead Institute of Medical weakness). In each content area, we also discuss the spanning functional movement disorder and func- Research, The Children’s tional limb/face weakness. We use a transdiagnostic Hospital at Westmead, Sydney implications of recent advances and suggest future Medical School, Westmead, New directions that will help continue the momentum of the approach across the range of functional motor South Wales, Australia past decade. In diagnosis, a major advance has been symptoms given high phenotypic overlap across 4NIH, NINDS, Bethesda, the emphasis on rule- in physical signs that are specific populations (eg, functional tremor with concurrent Maryland, USA for hyperkinetic and hypokinetic functional motor functional weakness in the same limb).S3 Isolated 5Psychiatry and Neurology, Rhode Island Hospital, symptoms. Mechanistically, greater importance has functional (psychogenic non- epileptic/dissociative) Providence, Rhode Island, USA been given to determining ’how’ functional neurological seizures, functional speech/voice disorder, func- symptoms develop, highlighting roles for misdirected tional cognitive disorder, functional sensory deficits copyright. Correspondence to attention, expectation and self- agency, as well as and the spectrum of functional somatic disorders Dr W Curt LaFrance, Jr, abnormal influences of emotion/threat processing brain are beyond the scope of this article and have been Psychiatry and Neurology, areas on motor control circuits. Aetiologically, while reviewed elsewhere.S4 S5 Sections here detail recent Rhode Island Hospital, Providence, RI 2903, USA; roles for adverse life experiences remain of interest developments in diagnosis, mechanisms, aetiolog- william_ lafrance_ jr@ brown. edu in mFND, there is recognition of other aetiologic ical factors, treatments and stigma in patients with contributors, and efforts are needed to investigate links mFND. In each content area, future directions are Received 30 December 2020 between aetiological factors and mechanisms. This also suggested, aimed at continuing the momentum Revised 8 February 2021 of the past decade. Accepted 23 February 2021 decade has seen the first randomised controlled trials Published Online First 15 March for physiotherapy, multidisciplinary rehabilitation and 2021 psychotherapy performed in the field, with consensus recommendations for physiotherapy, occupational DIAGNOSIS http://jnnp.bmj.com/ therapy and outcome measures also published. Across New developments patients, clinicians, healthcare systems and society, Establishing the diagnosis of mFND has been made S6 stigma remains a major concern. While challenges more practicable, as physical examination find- persist, a patient- centred integrated clinical neuroscience ings with diagnostic specificity have been identified approach is primed to carry forward the momentum of (eg, Hoover’s sign with an estimated specificity 6 the past decade into the future. of 95.7%–99.9%). Educational efforts have also made neurologists more confident in their ability to on September 30, 2021 by guest. Protected accurately diagnose patients with mFND, discour- aging extensive laboratory testing unless a comorbid INTRODUCTION neurological disorder is suspected.7 Functional neurological disorder (FND), also The Diagnostic and Statistical Manual of Mental known as conversion disorder, is a common, Disorders- Fifth Edition (DSM-5) criteria for FND disabling and costly condition at the intersection include the diagnostic features of inconsistency of neurology and psychiatry.1 2 While of interest to and incongruity on examination, emphasising posi- founding leaders across the clinical neurosciences in tive neurological features; identifying an under- © Author(s) (or their employer(s)) 2021. No the late 19th century, FND was largely abandoned lying psychological trauma has been relegated to a 1 S3 S6 commercial re-use . See rights by academics and researchers alike during the late discussion note and removed as a criterion. and permissions. Published 20th century.S1 The rationale for these difficulties Inconsistency refers to changes in manifestation by BMJ. were based in part on a Cartesian dualism of the over time, such as variation in tremor frequency To cite: Perez DL, Edwards brain and mind, limited neuropathophysiologic and amplitude or remissions and exacerbations. S2 MJ, Nielsen G, et al. J Neurol understanding and few evidence- based treatments. Incongruity refers to discordance with other known Neurosurg Psychiatry In the 21st century, a resurgence of interest in FND neurological disorders or human anatomy and 2021;92:668–677. has occurred, catalysed by improved diagnostic physiology. Additional general diagnostic features 668 Neuropsychiatry J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2020-323953 on 15 March 2021. Downloaded from Table 1 Positive clinical features (phenotype specific) and useful adjunctive laboratory tests for the diagnosis of functional movement disorder Functional motor symptom Clinical features Laboratory tests Tremor Entrainment (tremor takes on the rhythm of paced movements performed with another Clinical neurophysiological measurements can quantify entrainment, body part) pause with quick movement, variability, tonic contraction at onset, Pause with quick movement of another limb increase amplitude with weighting and coherence between limbs Variability in frequency, amplitude Tonic contraction at onset Increase in amplitude with weighting Coherence of tremor between two limbs Whack- a- mole sign (restraint of tremor induces tremor in another body part) Myoclonus Variability and long duration of the movement Long electromyography bursts Complex movement Presence of a Bereitschaftspotential (readiness potential) before the Appearance of startle jerk Long and variable latency of stimulus induced jerks With stimulus- induced jerks: long and variable latency Jerks when tendon hammer stops short of contact Tic Lack of urge Normal Bereitschaftspotential Lack of voluntary control (suppressibility) Dystonia Certain patterns such as fixed dystonia or pulling lip to one side Normal blink reflex recovery Normal plasticity with paired associative conditioning Parkinsonism Marked slowness or incoordination in examination but not with normal movements Normal dopamine transporter scan Gegenhalten (variable resistance during passive movement) Lack of sequence effect (slowness without amplitude decrement during repetitive movements) Huffing and puffing sign (fatigue with minimal effort) Gait disorders Specific patterns including knee buckling, dragging a monoplegic leg, astasia- abasia, None excessive slowness and atypical limping Better balance than claimed, including improvement with distraction Either no falls, controlled falls or falling toward support Chair test (can use legs to move a chair better than walking) are distractibility and suggestibility. Most other diagnostic signs intermittent lip deviation to one side15 are commonly identified are phenotype specific and can be augmented by certain clinical functional patterns. Functional facial spasm, a common stroke copyright. neurophysiological tests.S7 Clinical neurophysiological tests (eg, mimic, is characterised by platysma hyperactivation, jaw devia- electromyography- assisted identification of tremor pause during tion and ipsilateral eyebrow depression.15 ballistic movements) can either objectify bedside observations or In support of the stability of an mFND diagnosis based on identify features that clinicians cannot readily appreciate.8 examination signs, a 14- year prospective study in 76 patients Positive signs on examination that characterise functional limb with functional limb weakness showed only a 1% misdiagnosis weakness (and functional sensory and gait disorders) have been rate.16 Notably, some patients have both functional neurolog- analysed for their statistical properties (including sensitivities ical
Recommended publications
  • Presentation and Care of a Family with Huntington Disease in a Resource

    Presentation and Care of a Family with Huntington Disease in a Resource

    Charles et al. Journal of Clinical Movement Disorders (2017) 4:4 DOI 10.1186/s40734-017-0050-6 RESEARCHARTICLE Open Access Presentation and care of a family with Huntington disease in a resource-limited community Jarmal Charles1†, Lindyann Lessey1†, Jennifer Rooney1†, Ingmar Prokop1, Katherine Yearwood1, Hazel Da Breo1, Patrick Rooney1, Ruth H. Walker2,3 and Andrew K. Sobering1* Abstract Background: In high-income countries patients with Huntington disease (HD) typically present to healthcare providers after developing involuntary movements, or for pre-symptomatic genetic testing if at familial risk. A positive family history is a major guide when considering the decision to perform genetic testing for HD, both in affected and unaffected patients. Management of HD is focused upon control of symptoms, whether motor, cognitive, or psychiatric. There is no clear evidence to date of any disease-modifying agents. Referral of families and caregivers for psychological and social support, whether to HD-focused centers, or through virtual communities, is viewed as an important consequence of diagnosis. The experience of healthcare for such progressive neurodegenerative diseases in low- and middle-income nations is in stark contrast with the standard of care in high-income countries. Methods: An extended family with many members affected with an autosomal dominantly inherited movement disorder came to medical attention when one family member presented following a fall. Apart from one family member who was taking a benzodiazepine for involuntary movements, no other affected family members had sought medical attention. Members of this family live on several resource-limited Caribbean islands. Care of the chronically ill is often the responsibility of the family, and access to specialty care is difficult to obtain, or is unavailable.
  • Parkinson's Disease: What You and Your Family Should Know

    Parkinson's Disease: What You and Your Family Should Know

    Parkinson’s Disease: What You and Your Family Should Know Edited by Gale Kittle, RN, MPH Parkinson’s Disease: What You and Your Family Should Know Table of Contents Chapter 1: Parkinson’s Disease: A Basic Understanding .....................................3 Chapter 2: Medical and Surgical Treatment Options ..........................................11 Chapter 3: Staying Well with Parkinson’s Disease ...............................................16 Chapter 4: Taking Charge of Your Health Care .....................................................22 Chapter 5: Accepting and Adapting to PD ..............................................................27 Chapter 6: Special Concerns of Persons with Young Onset Parkinson’s Disease ........................................................31 Glossary ........................................................................................................................36 About the National Parkinson Foundation ................................................................................38 Acknowledgements ....................................................................................................................... 40 Parkinson’s Disease: What You and Your Family Should Know Chapter 1 Parkinson’s Disease’s: A Basic Understanding Parkinson’s disease (PD) is a complex disorder of the brain. Because it is a disease that affects the brain, it is classified as a neurological disorder – neurological means “related to the nerves” – and the doctors who specialize in diseases that affect the
  • Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 1

    Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 1

    ORIGINAL CONTRIBUTION Prevalence and Classification of Mild Cognitive Impairment in the Cardiovascular Health Study Cognition Study Part 1 Oscar L. Lopez, MD; William J. Jagust; Steven T. DeKosky, MD; James T. Becker, PhD; Annette Fitzpatrick, PhD; Corinne Dulberg, PhD; John Breitner, MD; Constantine Lyketsos, MD; Beverly Jones, MD; Claudia Kawas, MD; Michelle Carlson, PhD; Lewis H. Kuller, MD Objective: To examine the prevalence of mild cogni- was classified as either MCI amnestic-type or MCI mul- tive impairment (MCI) and its diagnostic classification tiple cognitive deficits–type. in the Cardiovascular Health Study (CHS) Cognition Study. Results: The overall prevalence of MCI was 19% (465 of 2470 participants); prevalence increased with age from Design: The CHS Cognition Study is an ancillary study 19% in participants younger than 75 years to 29% in those of the CHS that was conducted to determine the pres- older than 85 years. The overall prevalence of MCI at the ence of MCI and dementia in the CHS cohort. Pittsburgh center was 22% (130 of 599 participants); prevalence of the MCI amnesic-type was 6% and of the Setting: Multicenter population study. MCI multiple cognitive deficits–type was 16%. Patients: We examined 3608 participants in the CHS Conclusions: Twenty-two percent of the participants who had undergone detailed neurological, neuropsycho- aged 75 years or older had MCI. Mild cognitive impair- logical, neuroradiological, and psychiatric testing to iden- ment is a heterogenous syndrome, where the MCI am- tify dementia and MCI. nestic-type is less frequent than the MCI multiple cog- nitive deficits–type. Most of the participants with MCI Main Outcome Measures: The prevalence of MCI was had comorbid conditions that may affect their cognitive determined for the whole cohort, and specific subtypes functions.
  • Capgras Syndrome Subbarayan Dhivagar1, Jasmine Farhana2

    Capgras Syndrome Subbarayan Dhivagar1, Jasmine Farhana2

    REVIEW ARTICLE Capgras Syndrome Subbarayan Dhivagar1, Jasmine Farhana2 ABSTRACT Capgras syndrome is a neuropsychiatric disorder, and it is also known as impostor syndrome. People who experience this syndrome will have an irrational belief that someone they know or recognize has been replaced by an impostor. The Capgras syndrome can affect anyone, but it is more common in females and rare cases in children. There is no prescribed treatment plan for people who are affected with Capgras syndrome, but there is a supportive psychotherapeutic measure to overcome this delusional disorder. Keywords: Impostor delusion, Misidentification syndrome, Prosopagnosia. Pondicherry Journal of Nursing (2020): 10.5005/jp-journals-10084-12151 INTRODUCTION 1,2Department of Mental Health Nursing, Kasturba Gandhi Nursing Capgras syndrome is a type of delusional disorder in which a person College, Sri Balaji Vidyapeeth, Puducherry, India holds a delusion that a friend, parents, spouse, or other close Corresponding Author: Subbarayan Dhivagar , Department of relatives or pet animals has been replaced by an identical impostor. Mental Health Nursing, Kasturba Gandhi Nursing College, Sri Balaji It is otherwise called as Capgras delusion or impostor delusion. Vidyapeeth, Puducherry, India, Phone: +91 8754733698, e-mail: It may be seen along with other psychiatric disorders such as [email protected] schizophrenia, schizotypal, and neuro-related disorders. How to cite this article: Dhivagar S, Farhana J. Capgras Syndrome. Pon J Nurs 2020;13(2):46–48. HISTORICAL VIEW Source of support: Nil It is named after Jean Marie Joseph Capgras (1873–1950). He was a Conflict of interest: None French psychiatrist, who was best known for the Capgras delusion; it was described in 1923 in a study published by him.
  • Functional Neurological Disorder: a Practical Guide to an Elusive Dx

    Functional Neurological Disorder: a Practical Guide to an Elusive Dx

    Roselyn W. Clemente Fuentes, MD, FAAFP; Functional neurological Merima Bucaj, DO, FAAFP; Sundonia J. W. Wonnum, PhD, LCSW disorder: A practical guide Eglin Family Medicine Residency, Eglin Air Force Base, FL (Dr. Clemente to an elusive Dx Fuentes); Abrazo Health Network Family Medicine Residency, Phoenix, AZ The complexity of this disorder poses a clinical challenge (Dr. Bucaj); Defense Health Headquarters, Falls Church, like few others. VA (Dr. Wonnum) roselynjan.w.fuentes. [email protected] CASE u The authors reported no PRACTICE John D,* a 25-year-old patient with an otherwise unremarkable potential conflict of interest RECOMMENDATIONS relevant to this article. medical history, describes 2 months of daily headache, lower- ❯ Avoid using stigmatizing extremity weakness, and unsteady gait that began fairly sud- The opinions and assertions terminology (eg, adding contained herein are the private denly during his first deployment in the US Army. He explains views of the authors and are not the prefix “pseudo” or the to be construed as official or as that these symptoms affected his ability to perform his duties adjective “hysterical”) to reflecting the views of the US Air and necessitated an early return stateside for evaluation and Force Medical Department or the characterize a suspected US Air Force at large. functional neurological treatment. disorder (FND) or a Mr. D denies precipitating trauma or unusual environmen- doi: 10.12788/jfp.0155 medically unexplained tal exposures. He reports that, stateside now, symptoms con- disorder. C tinue to affect his ability to work and attend to personal and ❯ Refrain from ordering family responsibilities. functional magnetic Asked about stressors, Mr.
  • Functional Neurological Disorder

    Functional Neurological Disorder

    Functional Neurological Disorder (FND) Learning guide Written by: Phuong Nhan, Registered Nurse Vincent Cheah, Registered Nurse Reviewed by: Dr Alexander Lehn, Neurologist Dr Megan Broughton, Neuropsychologist Dr Rian Dob, Neuropsychologist Dharsha Navaratnam, Physiotherapist Our Mission In the spirit of the Sisters of Mercy, the Mater Hospital offers compassionate service to the sick and needy, promotes an holistic approach to healthcare in response to changing community needs and fosters high standards in health-related education and research. Following the example of Christ the healer, we commit ourselves to offering these services to all without discrimination. Our Values Mercy: The spirit of responding to one another Dignity: The spirit of humanity, respecting the worth of each person Care: The spirit of compassion Commitment: The spirit of integrity Quality: The spirit of professionalism 2 Contents Functional Neurological Disorder learning guide 4 Aim ........................................................................................................ 4 Guide outline .......................................................................................... 4 Introduction to FND 5 What is FND? .......................................................................................... 5 A brief history of FND .............................................................................. 5 Glossary of key terminologies 6 Who is at risk? 7 Symptoms of FND 8 Functional motor disorders ....................................................................
  • Functional Cognitive Disorder: Dementia's Blind Spot

    Functional Cognitive Disorder: Dementia's Blind Spot

    doi:10.1093/brain/awaa224 BRAIN 2020: Page 1 of 9 | 1 UPDATE Functional cognitive disorder: dementia’s blind Downloaded from https://academic.oup.com/brain/advance-article/doi/10.1093/brain/awaa224/5892366 by guest on 20 October 2020 spot Harriet A. Ball,1 Laura McWhirter,2 Clive Ballard,3 Rohan Bhome,4 Daniel J. Blackburn,5 Mark J. Edwards,6 Stephen M. Fleming,7 Nick C. Fox,8 Robert Howard,4 Jonathan Huntley,4 Jeremy D. Isaacs,6,9 Andrew J. Larner,10 Timothy R. Nicholson,11 Catherine M. Pennington,2 Norman Poole,9 Gary Price,12 Jason P.Price,13 Markus Reuber,5 Craig Ritchie,2 Martin N. Rossor,8 Jonathan M. Schott,8 Tiago Teodoro,6,14 Annalena Venneri,5 Jon Stone2 and Alan J. Carson2 An increasing proportion of cognitive difficulties are recognized to have a functional cause, the chief clinical indicator of which is intern- al inconsistency. When these symptoms are impairing or distressing, and not better explained by other disorders, this can be conceptual- ized as a cognitive variant of functional neurological disorder, termed functional cognitive disorder (FCD). FCD is likely very common in clinical practice but may be under-diagnosed. Clinicians in many settings make liberal use of the descriptive term mild cognitive im- pairment (MCI) for those with cognitive difficulties not impairing enough to qualify as dementia. However, MCI is an aetiology-neutral description, which therefore includes patients with a wide range of underlying causes. Consequently, a proportion of MCI cases are due to non-neurodegenerative processes, including FCD. Indeed, significant numbers of patients diagnosed with MCI do not ‘convert’ to de- mentia.
  • What Is Schizophrenia?

    What Is Schizophrenia?

    What Is Schizophrenia? What is schizophrenia? Although currently classified as a mental illness, schizophrenia is now scientifically accepted as a neurobiological brain illness. A Syndrome Schizophrenia, a neurobiological brain syndrome, includes possibly hundreds of distinct brain diseases. These diseases are sometimes referred to as “schizophrenia spectrum disorders.” Symptoms vary greatly among different people. The most widely accepted theory of schizophrenia is that it is a neurodevelopmental disorder, which means that normal brain development during fetal life is disrupted due to various genetic factors and/or environmental factors. Schizophrenia usually starts in adolescence or early twenties in males and in the late 20s and early 30s in some females. A Brain Disorder While schizophrenia is clearly a neurological disorder like stroke, Parkinson’s Disease, Alzheimer’s Disease and others – schizophrenia is still classified as a mental illness. It should be emphasized that one of the most important jobs of the brain is to generate the mind, and thus all mental disorders such as schizophrenia, bipolar disorders, major depression or panic disorder are actually caused by abnormalities in brain structure and function. As Thomas Insel, MD – former Director of the National Institute of Mental Health – said, “Mental disorders are biological disorders involving brain circuits.” There are hundreds of “biotypes” within the schizophrenia syndrome, but they all share a similar phenotype of psychosis, cognitive deficits and negative symptoms. Clinical Features of Schizophrenia Schizophrenia affects about 1% of the world’s population, (60 million people, around the world). Symptoms of schizophrenia may include hallucinations (seeing, hearing or smelling things that are not really there) and delusions (persistent false beliefs, such as that someone plans to harm them or that the affected individual is a person is a prophet, or member of the CIA).
  • Quick Fact Sheet for Providers

    Quick Fact Sheet for Providers

    Please notify my Parkinson’s Doctor that I have been admitted to the hospital For more information, go to www.parkinsons.va.gov Parkinson's Disease: Quick Fact Sheet for Providers What is Parkinson's Disease? Parkinson's disease (PD) is a chronic, progressive, neurological disorder associated with loss of dopamine-generating cells in the brain that results in multiple and often, complex symptoms. It is mainly associated with loss of motor control—tremor, stiffness, slowness of movement, and/or balance problems. However, non-motor symptoms are frequently present. Not every patient with PD has the same symptoms or response to medications. To date there is no known cause and no cure. Important Nursing/Clinical Care Considerations for the PD patient Patients with PD typically need their medications at specific times during the day. Please do not skip doses or postpone doses, unless ordered by a neurologist. To avoid serious side effects and/or help prevent an increase in debilitating motor symptoms, patients should receive their medications on time, every time! When ordering medications, please write specific times (i.e. 10:00am, 2:00pm, 6:00pm) as per the patient's home schedule, instead of frequency (i.e. three times a day). Do not stop Parkinson's medications abruptly. Resume medications immediately following procedures, unless vomiting or severely incapacitated. If an antipsychotic is necessary, use quetiapine (Seroquel) or clozapine (Clozaril). To treat nausea, use trimethobenzamide (Tigan) and ondansetron (Zofran). Be alert for swallowing problems. Do falls risk assessments and prevention. Ambulate as soon as medically safe. Patients may need assistance.
  • Physical and Occupational Therapy

    Physical and Occupational Therapy Huntington’s Disease Family Guide Series Physical and Occupational Therapy Family Guide Series Reviewed by: Suzanne Imbriglio, PT Edited by Karen Tarapata Deb Lovecky HDSA Printing of this publication was made possible through an educational grant provided by The Bess Spiva Timmons Foundation Disclaimer Statements and opinions in this book are not necessarily those of the Huntington’s Disease Society of America, nor does HDSA promote, endorse, or recommend any treatment mentioned herein. The reader should consult a physician or other appropriate healthcare professional concerning any advice, treatment or therapy set forth in this book. © 2010, Huntington’s Disease Society of America All Rights Reserved Printed in the United States No portion of this publication may be reproduced in any way without the expressed written permission of HDSA. Contents Introduction Movement Disorders in HD 4 Cognitive Disorders 8 The Movement Disorder and Nutrition 9 Physical Therapy in Early Stage HD Pre-Program Evaluation 11 General Physical Conditioning for Early Stage HD 14 Cognitive Functioning and Physical Therapy 16 Physical Therapy in Mid-Stage HD Assessment in Mid-Stage HD 17 Functional Strategies for Balance and Seating 19 Physical Therapy in Later Stage HD Restraints and Specialized Seating 23 Accommodating the Cognitive Disorder in Later Stage HD 24 Occupational Therapy in Early Stage HD Addressing the Cognitive Disability 26 Safety in the Home 28 Occupational Therapy in Mid-Stage HD Problems and Strategies 29 Occupational Therapy in Later Stage HD Contractures 33 Hope for the Future 34 Introduction Understanding Huntington’s Disease Huntington’s Disease (HD) is a hereditary neurological disorder that leads to severe physical and mental disabilities.
  • POS-Psychoorganic Syndrome

    POS-Psychoorganic Syndrome

    Endocrinology & Metabolic Syndrome Opinion POS-Psychoorganic Syndrome Himabindhu Gude* Department of Biotechnology, Osmania University College of Science, Tarnaka, Hyderabad, Telangana, India caused changes in the brain by organic. The particular Psychoorganic syndrome is also known as organic component of the solvents causes neurological disorder and is psychosyndrome. It is a progressive disease comparable to difficult to isolate due to expose of many compositions, grades, dementia. It consists of psychopathological symptoms which are and purity of solvents. At the initial stage, asthenia is prevalent caused by brain disorders which involves in reduction of and the progress of the disorder is slow. Acute onset is memory and intellect. Psychoorganic syndrome occurs in diagnosed when a great amount of psychological symptoms atrophy of brain, and mostly during senile and presenile age surface. The last stage of this disorder is made up of numerous (e.g. senile dementia, presenile dementia, Alzheimer's disease). disorders, like dementia, Korsakov's syndrome, and includes There are several causes, like CNS damages to traumatic brain severe personality change such as depression, anxiety, memory injury, cerebrovascular diseases, intoxication, exposure to loss, and drastic change in intellect. Level of kindness, organic solvents such as toluene, tumors, chronic metabolic happiness, and insight are greatly affected in the final stage. disorders, encephalitis,and abscesses of the brain, also be found in case of diseases accompanied by convulsive seizures. Although the exact mechanisms that solvents have on the Psychoorganic syndrome occurs at any age but is most nervous system are not fully understood, the metabolisms of the pronounced in elderly presenile and senile age.
  • Specific Neurological Phenotypes in Autism Spectrum Disorders Are Associated with Sex Representation RESEARCH ARTICLE

    Specific Neurological Phenotypes in Autism Spectrum Disorders Are Associated with Sex Representation RESEARCH ARTICLE

    RESEARCH ARTICLE Specific Neurological Phenotypes in Autism Spectrum Disorders Are Associated with Sex Representation Esther Ben-Itzchak, Shay Ben-Shachar, and Ditza A. Zachor Autism spectrum disorder (ASD) is a heritable disorder occurring predominantly in males. The aim of this study was to compare sex differences in the prevalence of specific neurological phenotypes commonly described in ASD. The study included 663 participants, aged 18 months to 15 years, diagnosed with ASD. Neurological and behavioral assessments were performed using standardized tests, and obtaining medical, developmental, and familial histories from the parents. Phenotypes under investigation were macro- and microcephaly, developmental regression, minor neurological and musculoskeletal deficits (MNMD), and seizures. Male : female ratio in the ASD group was 6.7:1. No sex differences in autism severity, cognitive ability, and adaptive functioning were noted. Mean head circumference percentile for males (50.1 ± 25.6) was significantly larger than females (43.4 ± 30.2). Micro- and macrocephaly were more frequent in ASD than expected (5.9%; 18.1%, respectively). Microcephaly in females (15.1%) was significantly more prevalent than in males (4.5%). The prevalence of macrocephaly in both sexes did not differ significantly. Regression was noted in 30.2% of the females with ASD, significantly higher than in males (18.9%). MNMD was documented in 73.8% of the females, significantly higher than in males (57.1%). M:F ratio decreased in a group with two or more phenotypes (3.6:1), while male predominance was more significant in the group without phenotypes (13.6:1). Neurological phenotypes associated with ASD are more prevalent in females than in males, resulting in more complex clinical and neurological manifesta- tions in females.